Abu Dhabi, UAE: Sheikh Shakhbout Medical City (SSMC), one of the UAE’s largest hospitals for serious and complex care and a ...

A randomized controlled trial finds no clear benefit of adding bezlotoxumab to FMT in patients with IBD and recurrent C difficile infection.

Aeglea Biotherapeutics Inc. ( (SYRE) ) has released its Q3 earnings. Here is a breakdown of the information Aeglea Biotherapeutics Inc.

Direct costs associated with IBD include ambulatory visits to gastroenterologists, emergency department visits, admissions ...

Developing a vaccination program for infectious bursal disease virus (IBDV) challenges should consider the severity and ...

Alcohol can worsen Crohn’s disease symptoms, but the impact varies from person to person. It may depend on what and how much ...

Nordic Bioscience, a leading biomarker company, announced that its CPa9-HNE biomarker assay received a Letter of Support (LoS ...

Mirikizumab, a drug currently approved by the Food and Drug Administration (FDA) for the treatment of ulcerative colitis, ...

Alopecia areata was more likely to develop in patients with inflammatory bowel disease (IBD) who were taking anti–tumor necrosis factor (TNF) therapy at the onset of the condition.

Managed Healthcare Executive provides C-suite executives at health plans and provider organizations with news, analysis, insights, and strategies to pursue value-driven solutions.

Not everyone responds equally well to treatments for inflammatory bowel disease (IBD). What will work for individual patients ...

New research from ACG 2024 reveals that primary sclerosing cholangitis raises colorectal cancer risk even in patients without ...